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Background: Expression of transcription-factors as Slug and Sox9 was recently described to determine mammary
stem-cell state. Sox10 was previously shown to be present also in breast cancer. Protein overexpression of Slug,
Sox9 and Sox10 were associated with poor overall survival and with triple-negative phenotype in breast cancer.
In this study we tested the stability of Slug, Sox9 and Sox10 expression during chemotherapy and addressed their
prognostic role of in neoadjuvant treated primary breast-cancer and their correlation to pathological-response and
overall survival.
Methods: We analyzed immunohistochemical expression of Slug, Sox9 and Sox10 in tissue microarrays of 96 breast
cancers prior to and after neoadjuvant chemotherapy. Expression was evaluated in invasive tumor cells and in
tumor stroma and scored as 0, 1+, 2+ 3+. Expression-profile prior to and after chemotherapy was correlated to
overall survival (Kaplan Meier) and with established clinico-pathological parameter.
Results: Sox9, Sox10 and Slug were expressed in 82–96% of the tumor cells prior to chemotherapy. Slug was
expressed in 97% of the cases in tumor stroma before therapy. Change in expression-profile after chemotherapy
occurred only in Slug expression in tumor-cells (decreased from 82 to 51%, p = 0.0001, Fisher’s exact test). The other
markers showed no significant change after chemotherapy. Stromal Sox9 expression (0 to 2+) correlated to better
overall survival after chemotherapy (p = 0.004) and reached almost statistical significance prior to chemotherapy
(p = 0.065). There was no correlation between Sox9 and hormone-receptor expression. In multivariate-analysis, the
stromal Sox9 expression after chemotherapy proved to be an independent and better prognostic marker than
hormone-receptor status. Other clinico-pathological parameter (as HER2-status or pathological-stage) showed no
correlation to the analyzed markers.
Conclusion: Strong stromal Sox9 expression in breast cancer after chemotherapy was found to bear negative
prognostic information and was associated with shortened overall survival. Slug expression was significantly
changed (reduced) in samples after neoadjuvant chemotherapy.
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Prognosis for breast cancer has improved continuously
during the last decades but it is still one of the most fre-
quent causes of tumor related death in women in the
western world. Possible reasons of breast cancer mortality
are tumor dormancy after treatment followed by local, re-
gional or distant recurrence. Several factors as hormone
receptors, HER2 status, proliferation fraction predicting
outcome in preoperative setting were extensively exa-
mined in previous studies (Chen et al. 2013; Denkert et al.
2010; Lips et al. 2013; Payne et al. 2008; Teleki et al. 2013;
van Nes et al. 2012; Varga et al. 2005; Yoshioka et al.
2013). The role of transcription factors (TF) in breast can-
cer prognosis has been the subject of some previous stu-
dies (Ablett et al. 2012; Cimino-Mathews et al. 2013;
Giordano et al. 2012; Guo et al. 2012; Mego et al. 2012).
Slug (SNAI2), a transcriptional repressor, is member of
the Snail family of zinc finger proteins and capable to act
as a master regulator, altering expression of a number of
genes including E-cadherin, a transmembrane protein
which plays an important role in cell adhesion (Guo et al.
2012). The role of Slug in cancer developmental processes
has been highlighted in several publications (Markiewicz
et al. 2012; Mego et al. 2012; van Nes et al. 2012). It has
been discovered that Slug is involved in an early develop-
mental phenomenon known as ‘Epithelial to Mesenchymal
Transition’ or EMT, which results in the acquisition of an
invasive, mesenchymal phenotype by epithelial cells. It has
been postulated to play an important role in cancer
growth and metastases spreading (Guo et al. 2012). Slug
and Sox9 were shown to induce epithelial mesenchymal
transition (EMT) and their expression consistently defines
mammary stem cell state (Guo et al. 2012). Sox9 and
Sox10 are two of the 20 different human Sox genes that
also encode family of transcription factors (Chakravarty
et al. 2011; Muller et al. 2010; Smalley et al. 2013; Soady &
Smalley 2012). In cooperation with Slug, Sox9 can be used
to determine the mammary stem cell state (Soady &
Smalley 2012). Sox9, a nuclear TF, is often localized in cyto-
plasm of invasive and metastatic breast cancer (Chakravarty
et al. 2011). It has been seen that patients with elevated
Sox9 levels in cytoplasm suffer from faster tumor cell
proliferation and significantly shorter overall survival
(Chakravarty et al. 2011).
Sox10 was described last year to be present in invasive
breast cancer especially in triple negative phenotype
(Cimino-Mathews et al. 2013). Sox9, Sox10 and Slug were
shown to be associated with poor overall survival in breast
cancer (Cimino-Mathews et al. 2013; Guo et al. 2012).
In surgical pathology Sox10 - a TF that allows the sur-
vival and differentiation of neural crest cells into mature
cells - is honored to support the diagnosis of melanoma
and nerve sheath tumors (Mohamed et al. 2013; Shin
et al. 2012). Recently Sox10 labeling has been documentedin myoepithelial differentiated cells in salivary gland neo-
plasms and also in metaplastic triple negative breast can-
cers (Cimino-Mathews et al. 2013; Ivanov et al. 2013).
The aim of this study was to discover the prognostic
role of Slug, Sox9 and Sox10 in neoadjuvantly treated
breast cancer and the correlation to pathological response
and overall survival. Furthermore, we tested stability of
these markers during chemotherapy.
Materials and methods
Patient cohort
96 breast cancer patients, diagnosed by tissue core needle
or fine needle aspiration biopsy (FNAB) and treated with
preoperative neoadjuvant chemotherapy were selected con-
secutively between 1998 and 2009 out of the archives
of the Institute of Surgical pathology, University Hospital
Zürich, Switzerland. The treatment regimens encompassed
different modalities including Herceptin combined with
Taxol or 2 to 6 cycles of Fluorouracil- Epirubicin and/or
Cyclophosphamid/Epi-docetaxel.
For 64 out of 96 patients, formalin-fixed, paraffin-em-
bedded (FFPE) tumor blocks from preoperative core biop-
sies and corresponding postoperative operation specimens
were available. Core biopsies prior to neoadjuvant che-
motherapy without postoperative surgical specimens were
available in 17 patients. For 15 patients, postoperative sur-
gical specimens were available without previous core biop-
sies. Clinico-pathological data and follow up information
(2-10 years) on all 96 patients could be retrieved from the
pathological and clinical files.
75 tumors were histologically/cytologically diagnosed as
an invasive ductal carcinoma (75/96: 78%), 18 cases as inva-
sive lobular carcinoma (18/96: 19%), 2 more were catego-
rized as metaplastic squamous cell carcinoma (2/96: 2%)
and 1 case as a small cell carcinoma (1/96: 1%). The age of
the patients was ranged between 30 and 74 years; mean age
52 years. Histological grading could be done in 81 cases
using the modified Bloom and Richardson score: 38 of 96
carcinomas were poorly differentiated (grade 3), (40%), 42
cases were moderately differentiated (grade 2) (44%) and
one case was well differentiated (grade 1) (1%). In 15 cases
correct histological grading on the core biopsy was not pos-
sible due to the too small amount of tumor tissue.
Surgery was performed as follows: Mastectomy in 60 pa-
tients, segmentectomy, in 28 patients. Breast surgery was
combined with axillary dissection in all but 5 of these pa-
tients. Residual tumor tissue after completing preoperative
chemotherapy was determined as recommended in the
residual cancer burden guidelines as the percentage of
residual tumor cells distributed in the tumor bed area
(Symmans et al. 2007).
Details of clinic-pathological parameter are shown in
Table 1. Table with patient’s collective in more details
previously published (Teleki et al. 2013).
Table 1 Clinico-pathological parameter of the breast
cancer samples in the tissue micro arrays
N = 96 Prior to chemotherapy After chemotherapy
Tumor size cT1 1 (1%) ypT0 6 (6%)
-a ypT1 20 (21%)
-b -a 2
-c 1 -b 11
cT2 25 (26%) -c 7
cT3 22 (23%) ypT2 31 (32%)
cT4 41 (43%) ypT3 24 (25%)
-b 19 ypT4 7 (7%)
-d 22 -b 6
NA 7 (7%) -d 1
No surgery 8 (9%)
Nodal status cN0 10 (11%) pN0 25 (26%)
cN1 62 (64%) pN1 27 (28%)
cN2 pN2 12 (12%)
cN3 3 (3%) pN3 14 (15%)
no surgery 8 (9%)
NA 21 (22%) NA 10 (10%)
ER status Positive 68 (71%) Positive 59 (62%)
Negative 25 (26%) Negative 16 (17%)
NA 3 (3%) NA 21 (21%)
(ypT0 or no surgery)
PR status Positive 59 (62%) Positive 46 (48%)
Negative 34 (35%) Negative 29 (31%)
NA 3 (3%) NA 21 (21%)
(ypT0 or no surgery)
HER2 status Positive 28 (29%) Positive 18 (19%)
Negative 65 (68%) Negative 57 (60%)
NA 3 (3%) NA 21 (21%)
ypT0, no surgery
Abbreviations: NA not available, ER estrogen receptors, PR progesteron receptors.
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proved by the Ethical Committee of the Canton Zürich
(KEK- ZH NR: 2009-0065) and also by the Internal
Review Board of the Institute of Surgical Pathology.
Detection of hormone receptors (ER/PR) and HER2 status
Estrogen receptors (ER, clone 6F11) and progesterone
receptor (PR, clone 1A6) expression was determined using
the iVIEW DAB detection kit in Ventana Benchmark (all
from Ventana, Basel, Switzerland) immunostainer follo-
wing heat induced epitope retrieval in CC1 solution.
According the current guidelines, at least 1% nuclear posi-
tive tumor cells were considered to be positive (Hammond
et al. 2010).HER2 status was defined according to the initial and
the modified ASCO criteria using immunohistoche-
mistry (IHC) and/or fluorescence in situ hybridization
(FISH) (between 1998-2004 IHC complemented with
FISH, between 2004-2009 FISH only methdology).
For immunohistochemistry, the CB11 clone of Anti-
Her2 monoclonal antibody (Ventana) was used for auto-
mated immunostaining as mentioned above. Scoring was
used in agreement with the time current FDA and ASCO/
CAP guidelines (Lebeau et al. 2001; Wolff et al. 2007).
Cases with tumor cells of > 10% strong and complete
membrane staining were considered 3+, cases with mode-
rate and complete membrane staining tumor cells were
defined to be 2+. For FISH, the HER2 gene amplification
was tested using the dual color FISH kit of PathVision
(Vysis, Abbott AG, Baar, Switzerland) following the manu-
facturer’s protocol. FISH reactions were evaluated using
an Olympus computer guided fluorescence microscope
(BX61, Olympus AG, Volketswil, Switzerland). Scoring
was done following the time current FDA and ASCO/
CUP guidelines: amplified status was diagnosed when
ratio (between HER2 gene and chromosome 17) was >2.0
(until 2007) resp. >2.2 (from 2008).
Tissue microarray construction
All cases were re-evaluated on hematoxylin-eosin (HE)
stained sections of the FFPE tumors for suitability for the
tissue microarray (TMA). Tumor tissues from 81 patients
prior to chemotherapy and tumor samples from 79 pa-
tients after chemotherapy were arrayed into two TMA
blocks using methodology described earlier (Kononen
et al. 1998; Theurillat et al. 2007). Matched tissue samples
before and after neoadjuvant chemotherapy were available
for 64 patients. From every patient duplicated cores of
tissue samples were arrayed into the cores.
Immunohistochemistry detection Slug, Sox9 and Sox10
Slug, Sox9 and Sox10 were detected using immunohisto-
chemistry on the fully automated Ventana Benchmark
autostainer following the manufacturers’ instructions. Fol-
lowing antibodies was used: Slug (Cell Signaling Tech-
nology, C19G7, 1:100), Sox9 (Millipore, AB5535, 1:400),
Sox10 (1:50, Santa Cruz Biotechnology, Santa Cruz CA).
IHC stains for Slug and Sox9 were homogenous across
entire tumor areas.
Expression for all three markers was evaluated in inva-
sive tumor cells and in tumor stroma and scored as 0, 1+,
2+ 3+. Expression profile prior to and after chemotherapy
was correlated to overall survival (Kaplan Meier) and with
established clinico-pathological parameter.
Statistical analyses
SPSS 15.0 software was used for statistical comparisons
(SPSS, Inc., Chicago, IL, USA). Categorical data were
Table 2 Distribution of marker expression in tumor and
stroma, distinguishing between 4 different expression
groups such as 0 = no expression, 1+ low expression, 2+
intermediate expression, 3+ strong expression
n = 84 SOX9 SOX9 SLUG SLUG SOX10
(pre) Tumor Stroma Tumor Stroma Tumor
pre 0 11 65 15 3 5
(13%) (77%) (18%) (3%) (6%)
pre 1+ 15 8 35 8 15
(18%) (10%) (41%) (10%) (18%)
pre 2+ 35 7 30 25 32
Riemenschnitter et al. SpringerPlus 2013, 2:695 Page 4 of 8
http://www.springerplus.com/content/2/1/695analyzed using Chi-Square test. Spearman rank correlation
was used to correlate Slug, Sox9, Sox10 expression and
clinic-pathological parameters (stage and grade, hormone
receptor status, Her2 status). Kaplan-Meier method was
used to calculate overall survival with evaluation of statis-
tical significance by log rank test. Multivariate analysis
was performed using Cox regression method with 95%
confidence intervals by including Sox9 and hormone re-
ceptor status both of before and after chemotherapy.
These parameters did not correlate directly each other.
Results were statistically significant at p values of < 0.05.
Bonferroni correction was not applied.(41%) (8%) (36%) (30%) (38%)
pre 3+ 23 4 4 48 32
(28%) (5%) (5%) (57%) (38%)
n = 82
(post)
post 0 10 65 40 8 7
(12%) (79%) (49%) (10%) (55)
post 1+ 22 14 24 27 22
(26%) (17%) (29%) (33%) (26%)
post 2+ 35 3 18 44 27
(42%) (3%) (22%) (54%) (33%)
post 3+ 17 1 0 3 28
(20%) (1%) (0%) (3%) (34%)Results
Sox9, Sox10 and Slug expression before and after
neoadjuvant treatment and stability of expression profile
during chemotherapy
Sox9: Before treatment 87% (73 of 84 cases) of the
tumors cells were Sox9 positive. 23% (19 of 84 cases)
showed expression of Sox9 in the stroma. After chemo-
therapy there were 88% (72 of 82 cases) tumors with
Sox9 expression in the tumor cells and 21% (19 of 84
cases cases) with expression in the tumor stroma.
Sox10 was positive in 94% of the cases (79 of 94 cases)
in the tumor cells before chemotherapy and 91% (75 of
82 cases) after treatment. There was no positivity in
stroma with Sox10.
Sox9 and Sox10 showed no significant change in ex-
pression profile after treatment and remained stable
stable during chemotherapy.
Slug was expressed in 82% of the tumor cells (69 of
84) and in 97% of the cases (81 of 84) in the tumor
stroma prior to chemotherapy. Slug showed relevant
changes after chemotherapy: 51% of the cases (42 of 82)
were Slug positive in the tumor cells. 74 of 82 cases
were positive for Slug in the stroma (90%). Strong (score
3) positivity in stroma decreased form 57% (48 of 84) to
3% (3 of 82).
Details of scores of immunohistochemistry are shown
in Table 2. and in in graphical illustration in Figure 1.
Examples of immunohistochemical stains are illustrated
in Figure 2.Statistical analysis
Correlation of Slug, Sox9 and Sox10 expression to overall
survival (OS)
Sox9, Sox10 and Slug prior to and after chemotherapy
were correlated with overall survival (Kaplan-Meier).
Only the stromal Sox9 expression prior to and after
chemotherapy showed correlation with OS Cases with
0, 1+, 2+ expression of stromal Sox9 pre-chemotherapy
had a nearly significant better overall survival than those
of 3+ (p=0.065).Correlation of Slug, Sox9 and Sox10 expression to ER/PR
and HER2 status
ER and PR status prior to and after chemotherapy showed
correlation with overall survival (pER-pre=0.025; pER-
post=0.044; pPR-pre=0.045; pPR-post=0.067). ER and PR
status did not show correlation with Sox9 (chi square). ER
and PR expression showed positive correlation with each
other (p=0.002). Hormone receptor status and stromal
Sox9 prior to and after chemotherapy were involved sepa-
rately in the multivariate analysis (Cox regression). HER2
status did not correlate with overall survival in this cohort,
so it was ignored from multivariate analysis.
According to multivariate analysis, stromal Sox9 expres-
sion after chemotherapy proved to be an independent and
better (but negative) prognostic marker than hormone re-
ceptor status. Prior to chemotherapy the prognostic power
of stromal Sox9 is similar than the hormone receptor sta-
tus (Table 3). Cases with 0, 1+, 2+ expression of stromal
Sox9 post-chemotherapy had significantly better overall
survival than those of 3+ (p=0.004) Figure 3.
Change in Slug, Sox9 and Sox10 expression profile prior to
and after chemotherapy
Slug stromal expression (score 3) showed highly signifi-
cant changes after chemotherapy (dropped from 57% to
3%), p = 0.0001 (Fishers’ exact test).
Figure 1 The presence of Sox9, Sox10 and Slug in tumor and stroma was compared before and after treatment in our collectiv of
breast cancer patients. They are grouped in 4 categories of marker expression, to be specific: no expression = 0,low expression = 1+, moderate
expression = 2+, high expression = 3+.
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frequent after chemotherapy and proved also significant
(increased from 18% to 49%), p = 0.0029 (Fishers’ exact
test).
There was no relevant or significant change in the ex-
pression profile of Sox9 and Sox10 after chemotherapy.
Discussion
In our study we analyzed the prognostic role and stability
of transcription factors as Sox9, Sox10 and Slug in a co-
hort of preoperative chemotherapeutically treated breast
cancers. We could show in this cohort that strong stromalFigure 2 Immunohistochemical expression of Sox9 and Slug in tissue
in stroma.Slug expression was instable during chemotherapy and
postoperative stromal Sox9 expression was significantly
associated with shortened overall survival.
We are not aware of any studies in the literature, sho-
wing association between these transcription factors and
prognosis in a preoperative treated breast cancer cohort.
In the last two years different studies addressed to the Sox
genes (Chakravarty et al. 2011; Muller et al. 2010; Soady &
Smalley 2012). It was demonstrated that these genes play
an important role in cancer development as well. Differen-
tiated mammary luminal cells expressing both Sox9 and
Slug, an EMT-associated transcription factor, were able tomicroarrays showed in tumor compared to the expression
Table 3 Multivariate Cox regression analysis of hormone
receptor status and stromal Sox9 expression before and
after chemotherapy
Parameters P-value HR 95% CI
Lower Upper
ERpre 0.052 3.139 0.988 9.969
Sox9pre stroma 0.063 0.234 0.050 1.081
PRpre 0.015 0.227 0.069 0.746
Sox9pre stroma 0.029 0.169 0.034 0.834
ERpost 0.077 2.796 0.893 8.753
Sox9post stroma 0.006 0.037 0.004 0.384
PRpost 0.223 2.062 0.644 6.609
Sox9post stroma 0.034 0.082 0.008 0.833
pre: before chemotherapy; post: after chemotherapy.
HR: hazard ratio; CI: confidence intervals.
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stem cells and reconstitute an entire mammary gland
(Guo et al. 2012). Meanwhile, showing stem cell charac-
teristics such as self-renewal and multi- potency, Sox10 is
one of the most studied Sox family genes, mainly because
of their role in the survival of neural crest cells and
compilation into neural-crest-derived melanocytes and
glia (Cimino-Mathews et al. 2013; Ivanov et al. 2013).
Invasive breast carcinomas, especially those with triple
negative hormone expression and metastases seem to
be supportive for myoepithelial differentiation (Cimino-
Mathews et al. 2013; Ivanov et al. 2013). Expression of
Sox9, Sox10 and Slug was seen in 82-96% of the tumor
cells prior to chemotherapy in our study, further suppor-
ting the fact that the transcription factors are highly active
in the breast cancer tissue.
It was described in a recent work of A. Cimino-Mathews
et al., that Sox10 is also expressed in breast carcinomas,
mainly in triple negative cases, changing the previous viewFigure 3 Kaplan Meier curves in stromal SOX9 expression. A: Cumulat
compared to high expression (3+) und moderate/ no expression (0, 1+, 2+), lon Sox10 being exclusively expressed by melanocytic
lesions (Cimino-Mathews et al. 2013).
Our cohort is a mainly hormone receptor dominated
tumor collection. Interestingly, Sox10 was detected in a
high percentage of tumor samples (up to 91-94%). The
high expression of Sox10 might represent a rather unspe-
cific staining property of unknown biological significance
as staining intensity did not have any prognostic impact in
this patients’ cohort. Moreover, Sox10 remained stable
during chemotherapy showing neither correlation to over-
all survival nor to response to chemotherapy. This is most
likely due to the fact that hormone receptor positive
carcinomas of the breast, as was the case in our study, can
benefit from different therapeutic options than triple
negative or basal like cancers. Further prognostic role of
Sox10 in breast cancer, needs to be addressed in future
studies.
Co-expression of Slug and Sox9 in breast cancer was
found to correlate with rapid tumor growth and meta-
stasis spreading in a study earlier (Guo et al. 2012). In
other studies, the high expression of Sox9 was found to be
associated with higher histological grade and/or triple
negative phenotype and thus considered as prognostic
marker in adjuvant oncological settings (Chakravarty et al.
2011). In our cohort of neoadjuvantly treated breast can-
cers, strong Sox9 expression (score 3) in tumor stroma
significantly correlated with shortened overall survival
after completion of preoperative chemotherapy, further
supporting the hypothesis described by Guo et al (Guo
et al. 2012). The lack of correlation between weaker Sox9
scores and survival can be most likely explained by the
fact that our cohort included mainly hormone receptor
positive cases. Strong stromal Sox9 expression may be po-
tentially used as a prognostic marker additionally to con-
ventional prognostic parameter when assessing residual
tumor burden and response after chemotherapy.ive survival in months of Sox9 expression prior to chemotherapy was
og-rank P = 0.065. B: Post-chemotherapy survival in months, P = 0.004.
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in the stromal Slug (score 3) expression after chemothe-
rapy. Furthermore, we detected significantly more tumors
lacking Slug expression in the tumor cell postoperatively.
As Slug expression could not be correlated to any known
prognostic factors in our cohort, the biological relevance
of this phenomenon remains unclear at the moment.
The correlation of Sox9, Sox10 and Slug to other clas-
sical clinico-pathological parameters as hormone recep-
tors, HER2 and proliferation index could confirm that
Sox9 is an independent negative prognostic factor. This
finding may be used as additional information on overall
survival and therapy response in neoadjuvant treatment
setting.
In summary, our study shows, that strong stromal
SOX9 expression in breast cancer after neoadjuvant
chemotherapy bears negative prognostic information
and is associated with shortened overall survival. The
biological relevance of change in phenotype change
resp. in expression profile of Slug, both in stroma and
tumor cells, needs to be addressed in further studies.
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